{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T20:19:13Z","timestamp":1773951553614,"version":"3.50.1"},"reference-count":41,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2018,12,13]],"date-time":"2018-12-13T00:00:00Z","timestamp":1544659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Marine Drugs"],"abstract":"<jats:p>Non-small cell lung cancer (NSCLC) is among the leading causes of human mortality due to a lack of effective treatments. Conventional chemotherapies affect healthy cells and cause multidrug resistance, while tumors may eventually develop resistance to less-toxic targeted therapies. Thus, the need to develop novel therapies for NSCLC is urgent. Here, we show that Nile tilapia-derived Tilapia piscidin (TP) 4 is cytotoxic to a panel of NSCLC cells with different genetic profiles. We observed that TP4 triggers NSCLC cell death through the necrosis and combining TP4 with potent Epidermal growth factor receptor (EGFR)- tyrosine kinase inhibitors (TKI)s, Erlotinib, and Gefitinib, improved drug responses in EGFR-mutated NSCLC cells, but not in EGFR-wild-type NSCLC cells. This work provides novel insights into potential NSCLC treatments, which may utilize antimicrobial peptide TP4 as monotherapy or in combination with EGFR-TKIs.<\/jats:p>","DOI":"10.3390\/md16120506","type":"journal-article","created":{"date-parts":[[2018,12,14]],"date-time":"2018-12-14T03:58:17Z","timestamp":1544759897000},"page":"506","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Nile Tilapia Derived TP4 Shows Broad Cytotoxicity toward to Non-Small-Cell Lung Cancer Cells"],"prefix":"10.3390","volume":"16","author":[{"given":"Chen-Hung","family":"Ting","sequence":"first","affiliation":[{"name":"Marine Research Station, Institute of Cellular and Organismic Biology, Academia Sinica, Ilan 262, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jyh-Yih","family":"Chen","sequence":"additional","affiliation":[{"name":"Marine Research Station, Institute of Cellular and Organismic Biology, Academia Sinica, Ilan 262, Taiwan"},{"name":"The iEGG and Animal Biotechnology Center, National Chung Hsing University, Taichung 402, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2018,12,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"418","DOI":"10.3945\/an.116.012211","article-title":"World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015","volume":"7","author":"McGuire","year":"2016","journal-title":"Adv. Nutr."},{"key":"ref_2","unstructured":"Noone, A.M., Howlader, N., Krapcho, M., Miller, D., Brest, A., Yu, M., Ruhl, J., Tatalovich, Z., Mariotto, A., and Lewis, D.R. (2018, September 10). SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, MD, Available online: https:\/\/seer.cancer.gov\/csr\/1975_2015\/."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1200\/JCO.2010.28.8126","article-title":"The evolving role of histology in the management of advanced non-small-cell lung cancer","volume":"28","author":"Langer","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_4","first-page":"S463","article-title":"The pivotal role of pathology in the management of lung cancer","volume":"5","author":"Davidson","year":"2013","journal-title":"J. Thorac. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1056\/NEJMoa040938","article-title":"Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib","volume":"350","author":"Lynch","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1126\/science.1099314","article-title":"EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy","volume":"304","author":"Paez","year":"2004","journal-title":"Science"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"13306","DOI":"10.1073\/pnas.0405220101","article-title":"EGF receptor gene mutations are common in lung cancers from \u201cnever smokers\u201d and are associated with sensitivity of tumors to gefitinib and erlotinib","volume":"101","author":"Pao","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/jnci\/dji055","article-title":"Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers","volume":"97","author":"Shigematsu","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1158\/0008-5472.CAN-04-4235","article-title":"Somatic mutations of the HER2 kinase domain in lung adenocarcinomas","volume":"65","author":"Shigematsu","year":"2005","journal-title":"Cancer Res."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Pao, W., Miller, V.A., Politi, K.A., Riely, G.J., Somwar, R., Zakowski, M.F., Kris, M.G., and Varmus, H. (2005). Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med., 2.","DOI":"10.1371\/journal.pmed.0020073"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Pao, W., Wang, T.Y., Riely, G.J., Miller, V.A., Pan, Q., Ladanyi, M., Zakowski, M.F., Heelan, R.T., Kris, M.G., and Varmus, H.E. (2005). KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med., 2.","DOI":"10.1371\/journal.pmed.0020017"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJMoa1411817","article-title":"AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer","volume":"372","author":"Janne","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1056\/NEJMoa1413654","article-title":"Rociletinib in EGFR-mutated non-small-cell lung cancer","volume":"372","author":"Sequist","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1200\/JCO.2009.24.7049","article-title":"Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer","volume":"28","author":"Jackman","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1177\/1758834016631531","article-title":"Overcoming resistance to first\/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancer","volume":"8","author":"Romanidou","year":"2016","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1056\/NEJMoa044238","article-title":"EGFR mutation and resistance of non-small-cell lung cancer to gefitinib","volume":"352","author":"Kobayashi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJM200507143530217","article-title":"EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer","volume":"353","author":"Shih","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6494","DOI":"10.1158\/1078-0432.CCR-06-1570","article-title":"Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors","volume":"12","author":"Balak","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa1612674","article-title":"Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer","volume":"376","author":"Mok","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/nm.3854","article-title":"Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M","volume":"21","author":"Thress","year":"2015","journal-title":"Nat. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1038\/sj.bjc.6604559","article-title":"Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer","volume":"99","author":"Tang","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1158\/2159-8290.CD-14-0326","article-title":"Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations","volume":"4","author":"Janjigian","year":"2014","journal-title":"Cancer Discov."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S1470-2045(15)00121-7","article-title":"Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): A phase 3 randomised trial","volume":"16","author":"Soria","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/415389a","article-title":"Antimicrobial peptides of multicellular organisms","volume":"415","author":"Zasloff","year":"2002","journal-title":"Nature"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"R102","DOI":"10.1186\/bcr3043","article-title":"Pleurocidin-family cationic antimicrobial peptides are cytolytic for breast carcinoma cells and prevent growth of tumor xenografts","volume":"13","author":"Hilchie","year":"2011","journal-title":"Breast Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"40329","DOI":"10.18632\/oncotarget.9612","article-title":"Targeting FOSB with a cationic antimicrobial peptide, TP4, for treatment of triple-negative breast cancer","volume":"7","author":"Ting","year":"2016","journal-title":"Oncotarget"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1016\/j.biomaterials.2014.01.032","article-title":"The mechanisms by which pardaxin, a,natural cationic antimicrobial peptide, targets the endoplasmic reticulum and induces c-FOS","volume":"35","author":"Ting","year":"2014","journal-title":"Biomaterials"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Peng, K.C., Lee, S.H., Hour, A.L., Pan, C.Y., Lee, L.H., and Chen, J.Y. (2012). Five Different Piscidins from Nile Tilapia, Oreochromis niloticus: Analysis of Their Expressions and Biological Functions. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0050263"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.biocel.2015.11.006","article-title":"Glycosylated Alpha-1-acid glycoprotein 1 as a potential lung cancer serum biomarker","volume":"70","author":"Ayyub","year":"2016","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.lungcan.2008.01.015","article-title":"HDL-cholesterol and the incidence of lung cancer in the Atherosclerosis Risk in Communities (ARIC) study","volume":"61","author":"Rosamond","year":"2008","journal-title":"Lung Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.bbagen.2012.02.015","article-title":"Characterization of dual effects induced by antimicrobial peptides: Regulated cell death or membrane disruption","volume":"1820","author":"Martins","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s00011-005-0062-9","article-title":"Mechanisms of cell death induced by the neutrophil antimicrobial peptides alpha-defensins and LL-37","volume":"55","author":"Aarbiou","year":"2006","journal-title":"Inflamm. Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4662","DOI":"10.4049\/jimmunol.175.7.4662","article-title":"Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37","volume":"175","author":"Tokumaru","year":"2005","journal-title":"J. Immunol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Kuo, H.M., Tseng, C.C., Chen, N.F., Tai, M.H., Hung, H.C., Feng, C.W., Cheng, S.Y., Huang, S.Y., Jean, Y.H., and Wen, Z.H. (2018). MSP-4, an Antimicrobial Peptide, Induces Apoptosis via Activation of Extrinsic Fas\/FasL- and Intrinsic Mitochondria-Mediated Pathways in One Osteosarcoma Cell Line. Mar. Drugs, 16.","DOI":"10.3390\/md16010008"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.regpep.2013.10.006","article-title":"Anti-tumor activities of the host-defense peptide hymenochirin-1B","volume":"187","author":"Attoub","year":"2013","journal-title":"Regul. Pept."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.regpep.2014.11.001","article-title":"Anti-cancer, immunoregulatory, and antimicrobial activities of the frog skin host-defense peptides pseudhymenochirin-1Pb and pseudhymenochirin-2Pa","volume":"194-195","author":"Mechkarska","year":"2014","journal-title":"Regul. Pept."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/aps.2010.162","article-title":"Enhancement of cytotoxicity of antimicrobial peptide magainin II in tumor cells by bombesin-targeted delivery","volume":"32","author":"Liu","year":"2011","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_39","first-page":"3052","article-title":"Anticancer Efficacy of Magainin2 and Analog Peptides","volume":"53","author":"Baker","year":"1993","journal-title":"Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/bip.20911","article-title":"Effects of net charge and the number of positively charged residues on the biological activity of amphipathic alpha-helical cationic antimicrobial peptides","volume":"90","author":"Jiang","year":"2008","journal-title":"Biopolymers"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Ting, C.H., Liu, Y.C., Lyu, P.C., and Chen, J.Y. (2018). Nile Tilapia Derived Antimicrobial Peptide TP4 Exerts Antineoplastic Activity Through Microtubule Disruption. Mar. Drugs, 16.","DOI":"10.3390\/md16120462"}],"container-title":["Marine Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-3397\/16\/12\/506\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:33:50Z","timestamp":1760196830000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-3397\/16\/12\/506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,13]]},"references-count":41,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["md16120506"],"URL":"https:\/\/doi.org\/10.3390\/md16120506","relation":{},"ISSN":["1660-3397"],"issn-type":[{"value":"1660-3397","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,13]]}}}